TAM
SGMO

Tocqueville Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Tocqueville Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,380
Closed -$7.81K – 553
2023
Q4 		$7.81K Sell
14,380
-400
-3% -$184 ﹤0.01% 517
2023
Q3 		$8.87K Hold
14,780
– – ﹤0.01% 513
2023
Q2 		$19.2K Sell
14,780
-2,800
-16% -$3.83K ﹤0.01% 533
2023
Q1 		$30.9K Hold
17,580
– – ﹤0.01% 526
2022
Q4 		$55.2K Hold
17,580
– – ﹤0.01% 569
2022
Q3 		$86K Hold
17,580
– – ﹤0.01% 584
2022
Q2 		$73K Sell
17,580
-2,000
-10% -$8.65K ﹤0.01% 652
2022
Q1 		$114K Hold
19,580
– – ﹤0.01% 690
2021
Q4 		$147K Sell
19,580
-5,000
-20% -$43.4K ﹤0.01% 721
2021
Q3 		$221K Sell
24,580
-1,240
-5% -$12.3K ﹤0.01% 689
2021
Q2 		$309K Sell
25,820
-270
-1% -$3.06K ﹤0.01% 631
2021
Q1 		$327K Sell
26,090
-150
-0.6% -$2.02K 0.01% 625
2020
Q4 		$409K Sell
26,240
-11,200
-30% -$131K 0.01% 571
2020
Q3 		$354K Sell
37,440
-1,200
-3% -$13K 0.01% 549
2020
Q2 		$346K Sell
38,640
-91,115
-70% -$845K 0.01% 543
2020
Q1 		$827K Sell
129,755
-5,180
-4% -$38.4K 0.02% 382
2019
Q4 		$1.13M Buy
134,935
+61,945
+85% +$570K 0.02% 437
2019
Q3 		$661K Sell
72,990
-68,747
-49% -$771K 0.01% 511
2019
Q2 		$1.53M Buy
141,737
+600
+0.4% +$6.38K 0.02% 418
2019
Q1 		$1.35M Buy
141,137
+22,100
+19% +$226K 0.02% 434
2018
Q4 		$1.37M Sell
119,037
-592,200
-83% -$7.36M 0.02% 422
2018
Q3 		$12.1M Buy
711,237
+370,297
+109% +$5.63M 0.15% 173
2018
Q2 		$4.84M Buy
340,940
+30,700
+10% +$510K 0.06% 306
2018
Q1 		$5.89M Sell
310,240
-355,650
-53% -$7.6M 0.08% 276
2017
Q4 		$10.9M Buy
665,890
+341,075
+105% +$5.07M 0.12% 196
2017
Q3 		$4.87M Sell
324,815
-30,200
-9% -$334K 0.06% 321
2017
Q2 		$3.12M Sell
355,015
-35,900
-9% -$230K 0.04% 366
2017
Q1 		$2.03M Buy
390,915
+143,250
+58% +$575K 0.02% 419
2016
Q4 		$755K Buy
247,665
+40,300
+19% +$147K 0.01% 530
2016
Q3 		$960K Sell
207,365
-81,975
-28% -$417K 0.01% 513
2016
Q2 		$1.68M Sell
289,340
-10,175
-3% -$64.8K 0.02% 442
2016
Q1 		$1.81M Sell
299,515
-4,050
-1% -$24.3K 0.02% 415
2015
Q4 		$2.77M Sell
303,565
-1,435
-0.5% -$11.1K 0.04% 371
2015
Q3 		$1.72M Sell
305,000
-156,620
-34% -$1.29M 0.02% 466
2015
Q2 		$5.12M Buy
461,620
+17,020
+4% +$219K 0.06% 307
2015
Q1 		$6.97M Buy
444,600
+370,800
+502% +$5.74M 0.08% 264
2014
Q4 		$1.12M Buy
73,800
+25,000
+51% +$304K 0.01% 559
2014
Q3 		$526K Sell
48,800
-9,000
-16% -$118K 0.01% 607
2014
Q2 		$883K Buy
57,800
+10,900
+23% +$157K 0.01% 606
2014
Q1 		$848K Buy
46,900
+16,900
+56% +$326K 0.01% 479
2013
Q4 		$417K Hold
30,000
– – 0.01% 620
2013
Q3 		$315K Buy
30,000
+10,000
+50% +$99.3K ﹤0.01% 759
2013
Q2 		$156K Buy
+20,000
New +$174K ﹤0.01% 884

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tocqueville Asset Management's SGMO Position: Q1 2024 in Review

Tocqueville Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2024, closing a stake of 14,380 shares — an estimated $7.81K sold.

Tocqueville Asset Management first reported a position in SGMO in Q2 2013 and held it in 43 quarters. The position peaked at $12.1M in Q3 2018. 131 funds tracked by Wall St. Rank hold SGMO as of Q1 2024.

  • Tocqueville Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2024 after selling out during the quarter.
  • Tocqueville Asset Management sold 14,380 SANGAMO THERAPEUTICS INC shares in Q1 2024, an estimated $7.81K.
  • Tocqueville Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 43 quarters.
  • Tocqueville Asset Management's SANGAMO THERAPEUTICS INC position peaked at $12.1M in Q3 2018.
  • 131 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2024.

Based on Tocqueville Asset Management's 13F filing for Q1 2024, filed 9 May 2024.